Sign up Australia
Proactive Investors - Run By Investors For Investors

Cellmid lays out major plan for product and distribution expansion

The company's shares are trading about 6% higher intra-day, at 46 cents.
products
Specifically formulated anti-aging hair solutions

Cellmid Limited (ASX:CDY) is anticipating a substantial increase in revenue in FY2019 following the planned expansion of distribution in the US and Japan and the increase in products in Australia.

USA - in-store placement from September 2018

Cellmid’s évolis range of products are specifically formulated anti-aging hair solutions which include shampoos, conditioners, sprays and activators.

For the first time évolis Professional products will be sold permanently in Neiman Marcus and Bloomingdales stores from September 2018.

The first Neiman Marcus stores designated for the full range of the évolis Professional products are Ala Moana (Hawaii), Fashion Island (California), Orlando (Florida), Northpark (Texas) and Houston (Texas).

These are flagship stores with well-trained sales associates and loyal customers.

READ: Cellmid secures partnership with Bloomingdales to sell évolis

Bloomingdales’ flagship store in New York will also carry the full évolis Professional range with other stores expected to come online in the next six months.

Japan - evolis launch in salons and pharmacies

The évolis branded FGF5 inhibitor anti-aging hair products will be launched in Japan in July 2018 (évolis Professional) and October 2018 (évolis pharmacy).

This is the first time that the Australian manufactured products will be exported to Japan and it follows a period of extensive product testing on Japanese customers assessing both beauty and therapeutic applications.

The sales channels for évolis Professional will be e-commerce and hair salons, while the évolis pharmacy range will be sold through independent chemists.

Australia and USA - new product launches

The évolis Professional range will be progressively introduced to suitable Australian pharmacies from July 2018.

This will increase the number of products sold from 4 to 15 within the brand in these pharmacies.

The évolis WHITE mask was launched in Australia in July 2018 and will be sold through pharmacies and salons in addition to Cellmid’s e-commerce platform.

Fillerina, the anti-aging transdermal filler product range with 11 variants, will be launched in Australian pharmacies progressively from September 2018.

Initial store locations have been secured with 70% of the first order already allocated to participating pharmacies.

The évolis Professional REVERSE Dry Shampoo is expected to be launched in Australia and USA in October 2018.

This product will be sold through all channels including premium retailers in the USA and pharmacies in Australia.

The évolis PROMOTE Protect spray will also be launched in beta test mode this month via e-commerce.

View full CDY profile View Profile

Cellmid Ltd Timeline

Related Articles

1528098797_Biotech-lab.jpg
June 05 2018
While tricky, the last year has seen Abzena increase its customer engagement with its integrated discovery, development and manufacturing service offering
1530537220_Blood-Test.jpg
July 03 2018
The research and diagnostic company develops cancer-detecting blood tests
1521490126_shutterstock_234586750.jpg
March 19 2018
The group has received key permits to allow cannabis - flowers and oils - to be imported into Australia from Aurora Cannabis Inc

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use